Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women

Bone

Volumn 86, Issue , 2016, Pages 98-105

  Imel, Erik A ^a   Liu, Ziyue ^b   McQueen, Amie K ^a   Acton, Dena ^a   Acton, Anthony ^a   Padgett, Leah R ^a   Peacock, Munro ^a   Econs, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Bone mineral density; DXA; FGF23; Fibroblast growth factor 23; Iron; Premenopausal women

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; IRON; PHOSPHORUS; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BONE DENSITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; FEMUR NECK; FIBROBLAST GROWTH FACTOR 23 GENE; GENE; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; IRON BINDING CAPACITY; LONGITUDINAL STUDY; MIDDLE AGED; PREMENOPAUSE; PROTEIN DETERMINATION; PROTEIN FUNCTION; RACE DIFFERENCE; YOUNG ADULT; BLOOD; CAUCASIAN; COHORT ANALYSIS; FEMORAL NECK; LUMBAR VERTEBRA; MULTIVARIATE ANALYSIS; PHYSIOLOGY;

ADULT; BONE DENSITY; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FEMUR NECK; FIBROBLAST GROWTH FACTORS; HUMANS; IRON; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MULTIVARIATE ANALYSIS; PREMENOPAUSE;

EID: 84960402261     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.03.005     Document Type: Article

References (38)

1. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19:429-435.
2. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005, 146(9):3883-3891.
3. Imel E.A., Peacock M., Gray A.K., Padgett L.R., Hui S.L., Econs M.J. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 2011, 96(11):3541-3549.
4. Farrow E.G., Yu X., Summers L.J., Davis S.I., Fleet J.C., Allen M.R., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(46):1146-1155.
5. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 2002, 87(11):4957-4960.
6. Imel E.A., Gray A., Padgett L., Econs M.J. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone 2014, 60:87-92.
7. Imel E.A., Hui S.L., Econs M.J. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Miner. Res. 2007, 22(4):520-526.
8. Ichikawa S., Baujat G., Seyahi A., Garoufali A.G., Imel E.A., Padgett L.R., et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am. J. Med. Genet. A 2010, 152A(4):896-903.
9. Shalhoub V., Ward S.C., Sun B., Stevens J., Renshaw L., Hawkins N., et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif. Tissue Int. 2011, 89(2):140-150.
10. Bansal N., Katz R., de Boer I.H., Kestenbaum B., Siscovick D.S., Hoofnagle A.N., et al. Influence of estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal women: the MESA study. J. Clin. Endocrinol. Metab. 2013, 98(12):4890-4898.
11. Jovanovich A., Bùžková P., Chonchol M., Robbins J., Fink H.A., de Boer I.H., et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the Cardiovascular Health Study. J. Clin. Endocrinol. Metab. 2013, 98(8):3323-3331.
12. Marsell R., Mirza M.A., Mallmin H., Karlsson M., Mellstrom D., Orwoll E., et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos. Int. 2009, 20(7):1167-1173.
13. Lane N.E., Parimi N., Corr M., Yao W., Cauley J.A., Nielson C.M., et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J. Bone Miner. Res. 2013, 28(11):2325-2332.
14. Fernández-Real J.M., Puig J., Serrano M., Sabater M., Rubió A., Moreno-Navarrete J.M., et al. Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS One 2013, 8(3).
15. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001, 60(6):2079-2086.
16. Merkel D., Moran D.S., Yanovich R., Evans R.K., Finestone A.S., Constantini N., et al. The association between hematological and inflammatory factors and stress fractures among female military recruits. Med. Sci. Sports Exerc. 2008, 40(11 Suppl):S691-S697.
17. Valenti L., Varenna M., Fracanzani A.L., Rossi V., Fargion S., Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos. Int. 2009, 20(4):549-555.
18. Kim B.J., Lee S.H., Koh J.M., Kim G.S. The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥45 years of age (KNHANES 2008-2010). Osteoporos. Int. 2013, 24(10):2627-2637.
19. Kim B.J., Ahn S.H., Bae S.J., Kim E.H., Lee S.H., Kim H.K., et al. Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J. Bone Miner. Res. 2012, 27(11):2279-2290.
20. Koller D.L., Ichikawa S., Lai D., Padgett L.R., Doheny K.F., Pugh E., et al. Genome-wide association study of bone mineral density in premenopausal European-American women and replication in African-American women. J. Clin. Endocrinol. Metab. 2010, 95(4):1802-1809.
21. Hui S.L., Koller D.L., Foroud T.M., Econs M.J., Johnston C.C., Peacock M. Heritability of changes in bone size and bone mass with age in premenopausal white sisters. J. Bone Miner. Res. 2006, 21(7):1121-1125.
22. Dale J.C., Burritt M.F., Zinsmeister A.R. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am. J. Clin. Pathol. 2002, 117(5):802-808.
23. Boinska J., Zekanowska E., Kwapisz J. Pro-hepcidin and iron metabolism parameters in multi-time blood donors. Int. J. Lab. Hematol. 2010, 32(5):483-490.
24. Asberg A., Thorstensen K., Mikkelsen G., Asberg A.E. The diagnostic accuracy of unbound iron binding capacity (UIBC) as a test for empty iron stores. Scand. J. Clin. Lab. Invest. 2013, 73(3):208-213.
25. Clinkenbeard E.L., Farrow E.G., Summers L.J., Cass T.A., Roberts J.L., Bayt C.A., et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J. Bone Miner. Res. 2014, 29(2):361-369.
26. Braithwaite V., Prentice A.M., Doherty C., Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int. J. Pediatr. Endocrinol. 2012, 2012(1):27.
27. Braithwaite V., Jarjou L., Goldberg G., Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone 2012, 50(6):1351-1356.
28. Bozentowicz-Wikarek M., Kocelak P., Owczarek A., Olszanecka-Glinianowicz M., Mossakowska M., Skalska A., et al. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?. Clin. Biochem. 2015, 48(6):431-436.
29. Lewis J.B., Sika M., Koury M.J., Chuang P., Schulman G., Smith M.T., et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J. Am. Soc. Nephrol. 2015, 26(2):493-503.
30. Abraham R., Walton J., Russell L., Wolman R., Wardley-Smith B., Green J.R., et al. Dietary determinants of post-menopausal bone loss at the lumbar spine: a possible beneficial effect of iron. Osteoporos. Int. 2006, 17(8):1165-1173.
31. Harris M.M., Houtkooper L.B., Stanford V.A., Parkhill C., Weber J.L., Flint-Wagner H., et al. Dietary iron is associated with bone mineral density in healthy postmenopausal women. J. Nutr. 2003, 133(11):3598-3602.
32. Maurer J., Harris M.M., Stanford V.A., Lohman T.G., Cussler E., Going S.B., et al. Dietary iron positively influences bone mineral density in postmenopausal women on hormone replacement therapy. J. Nutr. 2005, 135(4):863-869.
33. Guggenbuhl P., Deugnier Y., Boisdet J.F., Rolland Y., Perdriger A., Pawlotsky Y., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos. Int. 2005, 16(12):1809-1814.
34. Parelman M., Stoecker B., Baker A., Medeiros D. Iron restriction negatively affects bone in female rats and mineralization of hFOB osteoblast cells. Exp. Biol. Med. 2006, 231(4):378-386.
35. Di Stefano M., Chiabotto P., Roggia C., Garofalo F., Lala R., Piga A., et al. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J. Bone Miner. Metab. 2004, 22(1):53-57.
36. Mirza M.A.I., Karlsson M.K., Mellström D., Orwoll E., Ohlsson C., Ljunggren Ö., et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J. Bone Miner. Res. 2011, 26(4):857-864.
37. Mirza M.A., Alsio J., Hammarstedt A., Erben R.G., Michaelsson K., Tivesten A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler. Thromb. Vasc. Biol. 2011, 31(1):219-227.
38. Grethen E., Hill K.M., Jones R., Cacucci B.M., Gupta C.E., Acton A., et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin d, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J. Clin. Endocrinol. Metab. 2012, 97(5):1655-1662.